Pathological prognostic factors in prostate cancer by Cohen, Ronald Joseph
tPATHOLOGICAL PROGNOSTIC FACTORS IN .PROSTATFlCANCER
-------------~~-~-~---------------~.--~------------
Ronald Jos~~h cohen
A tb asis sub:mitti3dto the F'i'lculty of Medioine,
university of the Witwatersrand, fOr the degree
of dootor ()f ~hi1osopby in Mer.:iicine.
Johannesburg 1991
tABSTRACT
Adenocarcinoma of tbe prostat<:l is the
ccmnonest; cancer of the western male. Each
year more than 120 000 new cases are
reported in the United States alone,
togeth!:;;:-with more than 26 000 deathS.
Autopsy f'ltudies suggest that the majority
of prostatic cancer remains clinically
undetected, therefore propagating the
concept
disease.
of latent 'ii'er~uS 1'iggressive
Uore recent studies have
challenged this concept and }.:nlated tumour
aggression to tumour size ~nd grade. These
studies nowever concede thai;'~:v~n the most
anaplastic large cancers ~?egan as a small
probably Well ~ifferentiated tUlnour. Why
some small cancers progress and others do
not , has not been establishAd. Long term
prognosis and response to therapy can also
not be predicted by the histolOgY of the
t.umour.
The purpoSe Qf this thesis is to explore
new parameters which "lay provide more
reliable data with l'egard to prognosis I and
explain why some tumours prog:t'esswhile
others dO not. The thesis will also attempt
to explain why Some tumours l'flspondt1ell to
therapy and others not.
Nuoleolar Organizer Regions (NORs) whioh
represent speoific nucleic aoid regions
will be assessed with respect to benign and
malignant prostatio epithelium. NORs will
also be ihvestigated as
indicator.
a prognostio
Neuro"'endocrine cells in prostatio cancer,
a poorly recognized. entity win be stUdied.
These cells will be assessed as a
prognnstic factor
small tumours will
tumours with
neuro-endoorine
in prostatic cancers.
be compared to large
respect to their
status. Fina.lly the
biochemistry and distr;1)ution of the
MIUro-endocrine oell in normal prostates
will be examined.
It is proposed that the prostatic
neuro-endocrine cell plays a major role in
the dGvelopment and progression of
a<),gressiv(f;prostate cancer, and that this
cell be addressed in future st.udieS in this
field.
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tCHAPTER I
INTRODUCT!ON
The incidence of prostatic carcinoma. in most
wlS!stern societies is second only to that of lung
cancer, yet cancer of the ,prostate ranKS only third
as a cause of cancer deaths (1). Recent literature
suggests that in the united state:;;of America and
Western Europe prostate cancer has now become the
commonest malignant tumour and the second most
common cause of cancer deaths in mall;ls.In 1987
amonq malignant diseases affecting- American males
20% were due to cancer of the prostate. Carcinoma
of the prostatei however, accounts for only 10% of
cancer deaths in AInerican males (,2).'I'hisdisparity
between the incidence and mortality is an
indication of this tumour'S
biological activity. some patients
cancer progress rapidly and die
wide range of
with prostatic
within several
morrchs while others have a much slower progression
and ultimately
studies sugge~t
cancers remain
die of unrelated causes. Autopsy
that the majority of prostate
clinically undetected (3). 'I'hese
findings have led to the conoept Of latent canoer
versus aggresl;;iva cancer. A corollary of this
theory is that the latent and aggressive forms of
the disease i;lrehistologicall.y indistinguishable
- 1 -
(4). Many studies have attempted to identify
histological reatures which would indicate a poor
prognosis I so that the patient 11.iaybe treated
accordingly. OVer the past :2 decades tl'le
progression of tumour, related to tumour volume has
been meticulou:,;lY studied by McNeal et al (5).
While most resea.rchers accept; that as tumour.volume
increases, the likelihood of clinically manifest
cancer increases, the rate of tumour growth
varies considerably from one tumour to another. In
addition once a tumour reaches proportions enabling
it to produce clinical symptoms the overall
prognosis will once again vary trom one patient to
anoeher , In =,:', large study by Gleason et al (6), it
was convincingly demonstrated that those tumours
which were poorly differentiated and had an
anaplastic growth pattern had a slgnificantly worse
prognosis than tumoul.·s which {flere well
differentiated and closely resembled normal
prostatic acinar structures. The vast majority of
tumours in that study (2 585 of 2 911) were graded
major
with
pattern 2, 3 and 41 i.e., intermediate grade
an intermediate or unpredictable outcome.
Therefore, those patients who tell into group 1
(histologioally well differentiated carcinoma) and
group 5 (anaplastic carcinoma) in which the
prognosis could be reliably predicted, represented
only a smal~ minority.
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CRITIQUE OF 'l'IiEGLEASON SCORE
In 1977 a study (7) at 'l'heArmed For.ces Institute
of Pathology examined 584 cases of prostatic
carcinoma. These cases were graded according to the
Gleason system, and obserVations including those by
Gleason himse.If were compared.The;rewas an ove;rall
concordance of only 38%. A workshop in 1979 (8)
further addressed the issue of grading. The
conclusion of this workshop was to adopt the
Gleason s((ore for grading of aLL, prostate. cancer.
The wo;rkshop however recC)nunendedsome modifications
to the Gleason scoring system.
other grading systems that have been utilized
include Mostofi (9), the Gaeta Grading System
(10,11), The M D Anderson (1.2) , The Mayo Clinic
Grading System (13) and the Unive;rsity of Freiburg
Grading System (14).
LIMI'l'SOF GRADING SYSTEMS
prostatic adenocarcinoma is usually graded f;rom
tissue removed at the time of transurethral
;f resection or by transrectal or transpel'i~.eal need1.e
biopsy. Several studies have shown a poor
concordance between tumour grade on biopsy
- 3 -
specimens compared to :r:adicalp:t:;'ostatectomy(15,
16).
As trans-u:t:;'ethral
transition zone
this may reflect
biopsies (TURP) sample the
and central portion of the ~.land r
poorly on the peripheral
sUbcapsular zone where most investigators agree the
tumour arisee. A spuriously low grade of tumour may
therefore be given.
Prostate cancer has been shown to dedifferentiate
with time. with dedifferentiation the Gleason score
increases (17). The rate of dedifferentiation is
unpredictable and is an unknown factor in tumour
grading.
In view of the problems in grading systems newer
techniqu-=s have been ut:i.Uzec'i to predict the
prognosis in prostate cancer. One of these flow
cytometry CUi) , which with the determination of
ploidy may prove to pe of value in the
determination of prognosis in pros-tate cancer.
Ploidy :t:;'efersto the amount at chromatin material
present Ln cell nuclei. The tE:!rl1laneuploid refers
to a chromatin content tha.t is not Ii mUltiple of
th.e normal haploid {23} or diploid (46) chromOSome
number. The data available is however, not
concurrent. Correlation between ploidy and capsular
- 4 -
penetration has been shown (log). Several studies
have ahown a correlation between ploidy and grading
(20,21). A further study (22) examined ploidY of
fresh tissue from 34 radical prostatectomies and
found all organ confined tumour to be diploid.
However, Clf25 diploid cancers a had spread outside
the gland and 6 had nodal metastasis.. stevenson et
al (23) shoWE;idthat ploidY correlated sta'l:.istically
with survival in stage 01 caucer-s, The authors
however, were reluctant to l:ecol'Cllnendadjuvant"
therapy fOr aneuploid tumours. A large num..oer of
related stUdies (.24,25,16) con:f'irma relcttionsh;l.p
between ,.pr(:)gnosisand ploidy although in all
stUdies a Significant x1umberof diploid tumours had
a poor progl10Gis. These studies also indicate a
good correlation between survival in localizod
disease treated by l.~adj,oalsurgery and ploidy. Whe
cot't'elation with survival in more advanced diseaSe
t."t:!a.tedwith anti"'androgenswas poor.
Other recently developed histologioal. techniques
used to predict the outcome in prostate cancer"~i.'
inolUde nucl.eolar surface area (27) and nuclear
roundness factor (28,29,30 I ::n.). These parametet's,
partioularly the la.tter, require compl.ex imaqe
analysis equipment and is at present oal.ybein9'
per:t'or~edby one group of investigators at a'ohns
Hopkins Univer~ity. AS in the Case of ploidy these
.- s -
grading systems appear to be of most benefit in
predictin9 prognosis in early localized disease,
rather than in advanced cancer. Response to hormone
manipulation in advanced cancer remains
unpredictable.
In spite of the variety of grttding systems and
newer teonniques in predicting the outcome of
prostate canceJ:'it is the opinion of Oatalona at
alA (15) that ~rading of prostate cancer including
n(ilwe~methodS! have serious de:eicienclie$.These new
techniques appear to be no better than good
histological grading, What they achieve is
effective removal of observer sUbjectivit1' These
systems are however, at present beyond the
financial reach of most institutions. In addition
th$y do not provide new data on prostate Cancer
biology I nor do 'I::heysupply any new approach to the
treatment of the disease.
Probably, the most important pro<;1nostic pa:t'ameter
in pro$'cat(:)cancer. is tumout'st~~e. The TMN system
(16) was previously utilized t!.na this has bt!ien
superseded by the Whit.more\,1ewettstaging system
(:33p34,35). 'rumour ~tage in prostate oancer is
ce~tainly of major prognostic value and determines
What treatment is administered. HoweVer, within
aach tumour sta<;jG,prediction of long term survival
in the ind.ividutH case as well as response to
hormone manipulation is unrel.i6ble.
In View of
histological
the unsatisfacto~y results ot
prognostication in prostate canoer 4'
variety of biochemical parameters have been
attempted. t.rheseinclude serUm testosterone levels
and serum alkaline phosphatase (36). In early
prostate cancer (sta<;re A/B) tUltIou,r<;rl"adi.ngis
thought to be n\ost useful, While in more advanced
stages C and. D serum l'rostate Speoific Antigen
("PSA-II), an anti.gen specific to prostate epitheUum
is thought to be more important (~1f3ar39). Serum
PSA dtirtEll:'.I1d.nGtionfollowing' therapy enables fairly
accurate }?redict::Lonof tumoux recurrence. 'rhe
height of the serum l?SA prior tQ therapy <ioes not,
however, ;reliably prediot pro9nosi.s and is only
weaklY assoe;i.a.ted with tumour stagA. other
parameters inoluding tumour androgen receptor assay
(40,4t), 5-alpha"X'eduotase determination (42), and
a va:riQty of growth factors (43,44) have proved. to
bs d:l.sappointing as preoict! VEl prognostic indicas ~
Clinical non"'specifio pat'llmeters, includin9
haemi!:lglol:>.in c;letermination, patitmts per:eorm~U'1c$
stai:.llSI bone pain and the Elxtent of bone
metastases, have proved to be of prognostic valuEl
in advance<:'\ oat,oar aft.er in1tid l'l.o1::monal
manipUlation (45,46,41).
";1
In 1943 Huggins et.al. (413) donfirmed the
inhibitory effeots of orohideotomy and exogenous
oestrogen on the growth of prostate can.cer. I:>espita
the initiRlly endouraging results of luteinizing
hormone"'raleasing hormone (lIun~Hu) agonists (49)
very recent tindyet unpublishedstuqie~ have shown
this form of therapy to be little bette:!: then
",)rdhidedtomy••
What is required in prostate oanoer todaY is an
aocu:I;'ate,reliable alld readily repx-oduoible method
of pl·ognost:ioation. 'l1his luethod must not only
determine prognosis in tha inciividual patient, but
mU$t 1'I1soindicate a poss.i.bl.e!lew approadh to the
treatment of this disease, whioh has not a.ltered
signifioantly in 0\1'9),' 50 years;, tdeally this
parameter should be \'J~ thin the finanoia), reaoh. of
most prostate oanoar patients.
CHAPTER I!
PRO~OSED NEW PROGNOSTIC ~A~ETERS.
NUCLEOLAR ORGANIZER REGIONS
Nucleolar oX'ganizer regions ("NOR") are loops of
ribosomal RNA ooourring in the nuc~eoli Of oells
whioh ultimately prooess RNA genas (!SO). NORS have
been demotu:;tX'ai:.eQby si1vat st.ainingtechniques
(ItAgNORIi) and have been studied in numeroUS
)\H.'llignanttumours, namely malignant lymphoma (61) I
cutaneou$ melanooytio lesions (52), and a small
series of prostatic ~umours (53).The numbers and/or
shtt: Of NOR'S may refleot the synthetic aotivity of
oe11s, or ev~n their malignant potential (54). In a
pilot study AgNOR dounts in malignant and benign
pt'ostatic t.issue will be oompared. Should tn.is
stUdY reveal a signifioant differenoa between the
'\:.\10 groups, this parameteJ;' may be oJ:value in
predicting long term survival in this disease.
NEURO~ENDOCRXNE CELLS
Neuro""endoOl:'ineor paraorine oells of the human
.. 9 ...
tprostate haVe been identified by variotls
methods,predominantly
immunocytochemistry
silver stains and
(55,56,57,58/59). It is
believed that the prostatic Amine producing Uptake
and Decarooxylase (HAPUD") colls like those of the
gastro-intestlnal tract arise by divergent
differentiation, rathel.' than from a neural cres'l;:
primordial cell (60,61). Although these cells have
been identified in oenign prostatic tissue and in
prostate cancer the precise lOcalization of the
neu~o-endocrine cell in the normal prostate at the
various stages of prostatic growth, development and
hyperplasia has not. knowledge been stUdied. The
function of these cells remains unknown, although
they have been shown to contain copious amounts of
serotonin and a somatostatin-like peptide (57).
A single report by DiSant'Agnese at al. (57) has
indica't:ed that the neuro ....endocrine cell is
scattered randomly throughout the entire pt'ostate,
although present in somewhat greatet' numbers in the
main prostatic ducts. No neuro-endocrine cells have
been found in the seminal Ves;i.cleor ejaoulatoJ:'Y
duct. This report indicated that the number of
neuro-endocrine cells appear to vary from one
individual to another. No explanation was given ;for
thi13 variation in the cell population, out one
eXplanation ):tIayobe the duration of :fixation.
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Alth.ough, as mentioned in this report, some of the
material examined was well fixed, there was no
merrci.on as to the duration of fixation. It is well
established that proteins stored in formalin
fixative progressively lose their antigenicity
(62). The antigenic loss may begin within 24 hours
of fixation, and many markers of neuro-endocrine
cells are lost within 72 hours Of formalin
fixation.
The studies by DiSant'Agneee et al as indicated
were performed on prostate glands obtained at
radical cystectomy. The method Of section of. these
glands waS not described, and there was no mention
as to the patients' age. !t is presumed that these
cases represented an eldet'ly population wj,tha
significant incidence Of prostatio hyperplasia and
hypertropy, and it is questioned how many of the
prostates examined were in faot "normal". The
number of neuro~endoorine cells in the hyperplastic
tissue was also not commented upon. The authors did
not refer to the distribution of neuro~endocrine
oells in the prostatio peri-urethral gland zone,or
cent;,:;al210ne. In addition a group of younger
pati~mts was selected from an .autopsy series. The
tissU),es, unlike the previous cases, were so
autol~rsed.that immunoperoxidase stains oould not to
be p(~rformed, the authors relying on relatively
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insensitive silver stains. The immunoperoddase
stains select!1:!dwere based on ~olyclonal antibodies
whioh may oause signifioant baokground staining,
particularly on autopsy material. Background
staining and non~specific precipitation can result
in misinterpretation of these stains~ The author
did not oharacterize these cells with known
biologioal markers of prostatE!epithelium iW;lluding
PSz..and Prostatio Acid Phosphatase ("PAP"),
ANATOMY OF 'l'H:EPROSTA'rE
The prostate gland oorlslsts Of three major
glandular reg-iollS,a peripheral zone, a oetltral
zone and a transition zone (Fig. 1). The oentred
zone is related ttl the ejaculatot'yduct and is
resistant to the development of prostate oanoer
(63,64)• The peripheral zone oomprises
appro:x:imately70% of the prostate mass. Xot consj,sts
predominantly of acinar structures Which drain by a
series of du.ctsto the prostatio l.1:('ethra.These
ducts penetrate the postero-lateral recesses of the
urethral wall as well as the urethra from the base
of the verumontanum to the pX'ostat;.icapex (63). The
~eriphe.t'alZQne is most susceptible to inflammation
(65) and is the site of origin of mQst caroinoma~
(66). The periurethral zone compX'ises less than 5%
- :1.2 ...
of the ncrmat prostate. It consists of tiny ducts
and acinar structures soattered along the len~lthof
the proximal urethra. This zone appear-st\Oend
abruptly at the verumontanum. The transition zone
condsts Of two lobes immedlately adjacent to the
verumontanum. The periurethral g).andzone forms a
portion of +'.hetransition zone. The transition zone
and periurethral regions are exclusive sites of
benign noc;l1,11arhyperplasia ("BPa") (63). The aim of
this study is to accuratelY localize, quantitate
.and dooUment the distribution Of neuro"'endocrine
cells in the normal prostate. In addition prostatic
tissue f':'ompatients of different ages \'lillbe
compared. 'rhaeffeots of puberty and ageing on this
sUb-Population of cells can then be documented.
NlllURO"'ENDOCR;J;NlllCELLS :eN PROSTATE CANCER
With the utiliz~tion of modern immunohistochemioal
techniques neuro-endodrine dells have beGn
identified in approximate 50% of prostate Canders
(59). This study will assess the observation and
attempt to establish whether or not the
neuro-endoc:r.ine cell is of any prognostj,c value as
has been suggested by a eiingle report (67).
NeUro"'endocrine or paracrine cells produce a
variety Of peptides (1$8,69) some of t-lhichmay
stimUlate the growtb of (JellS.Small cell earcinoma
.. 1'3 ..
of the prostate which has been described in
isolated case reports (70,71) appears to be in part
a dedifferentiated neuro-e:ndocrine tumour. These
tumours have a uniformly poor prognosis and
frequently do not elaborate signi:eicant amounts of
PSA and PAP the usual markers of prostate cancer.
The tumours which will be studied are not small
oell ancers
In addi'l.,,;ion
tumour~ will
but usual prostatic adenocarcinomas.
the neuro~endocrine status of the
be Compared to curr~ntly utilized
prognostic parameters including clinical stage and
Gleason scoxe , The neuzo ...endocrine cell population
of clinically manifest as well as occult canoers
will be studied. The incidence of occult danoer is
approximately 50% in :males aged 50 years (72). As
the vast majority of these tumours will remain
occult and will not beco:me clinically manifest it
will be of value to compare these cases to those
with manifest ~arcino:ma.
PSA first isolated oy Wang et al (73) is a
glycoprotein with a moleoular weight of 34,000
daltons and is speoifio to prost&te tissue (74).
PSA has proven to be a reliable marJ'::erof pro'stat,e
cancer and :may be an indicator of effective
treatment (75). The effect of hormone therapy
appears to dl::ast.;\.callydacrease the produotion of
PSA and it seems that PSA may be androgen dependent
.. 1.4 ...
(75,76). '1'heproduction of PSA and PAP ~.n
neuro-endocrine cells in otherwiSe unrmarkable
adenocarcinoma has not been determined.One report
has documented PAP and PSA in a single prostatic
carcinoid t.umour (60). In this report. comparative
immunohistochemical staining was not undertaken and
it is quast.Lonab.l.ewhether every cell pr.esent was
neuro..endocrine.
Virtually all prost.atecancers will demonstrate PSA
(69,77,78) albeit focally, on direct
immunopero:l\:idasest~ininq. Serum PSA levels appear
to increase with advancing clinioal s"l;uge( '78).
Considerable overlap; however, exists within
clinical stages, and in the individual case, PSA
levelS are ot qUestiOl'labl.eaccuracy in predicting'
stage of disease. It is well described that
patients with advanced cancers may have only
minimally raised PS.A values (76,79), the
explanation for which is poorly addr€'sEled in the
literature.
The aim of this portion of the study is to
determine some of the biochemical characteristics
of the neuro-endocrine cell and to determine if
this cell },t'oducesPSA and PAP.
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t- 17-'B-OESTRADIOLI'
17-B-OESTRADIOL is an oestrogen produced from
circulating testosterone by peripheral tissues
including prostatic epithelium.r.rhefunction of this
oestrogen moleCUle in androgen sensitive tissues is
not known. In several studies (80,81,82) it was
Shown that 17-B-OESTRADIOL Lnoreased the number o~'
testosterone .recep'torsin dog prostatic tissue and
was necessary for normal Prostatic growth. The
measurement of in the cell17-B-OESTRADIOL
cytoplasm and nucleus may indicate indirectly those
prost.atic cells which are binding testosteroi'le.'l'his
may indicate those cells requiring testosterone for
cell metabolism. With a newthe ofUSe
anti-17-B-OES'I'RADIOL polyclonal antibody developed
for use in breast tumours (83), l7--B-OESTRAD£OL can
be assessed in prbstatic ceUs. Positivity in
l:wbstate cancez may thus indicatEl tumour dependence
on testosterone and predict response to hormone
thera.py.
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KEYa central z.oneperif'Ell:'!:1.J.zonetrans;Lt'l)n zone
e - ejaoulator'y duct
up ..proximal uret.hra.
dp - distal urethra
dp
Figu:t;'$1. Sagittal. section ot the prostate
(adapted from McNeal (63)
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tOHAPWE!{ IIt
STUDY I NuctEOLAR ORGANIZER REQ!ONS IN BENIGN
ANP MALIGNANT PROS~ATE TISSUE
Eleven oases of benign prostatio enlargement. and ll.
oases of prostatio oaroinoma were randomly selected
from the Johannesburg Hospital reClorCl.sfrom January
19a9 ",hrou9h to April l~S9. TWO 3 mioron seotions
were out and were taken to aqueous solution via
xyline and 9ra.ded alcohol.s.
All sections wera submltted to the A9NOR procedure
at r0011\t.emperatut'cafor 50 minutes (53) • Tha
reaction mi)(tut'e comprised a 1% form.io..aoid
solution in 2% 9'f!!latin.rz'hiswas oombined in a
proportion of 1"2 volumtaswith a tsO% silver nitrata
solution under darkroom conditions to prevent
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precipitation. counter staining was not per:t;ormecl,
and the sections were dehydt"ated and mounted in a
synthetio madi1.1nt.
The specinter:s Wet"e s'tained under oil intmeraion l.ens
at XIOOO magnifioation. One hu.ndred nu.cl.ei\I!e:ra
examined and a simple gratioule used to prevent
:recounting. '.t'henumbez' of AgNORs present in linil19
epithelial oells waS dooumented. AgNOR
p:re~ipitation in stromal, endothelial/and
inflamnlatory oells was disregal:'ded.
At cne salna time AgN()~ preoipitation granules were
assesSed, seotions from the malignant prostates
stained with haema.toxylin and eosin (!!HSlE" ) were
examined indepenaently by two pathologists. ThE)
tUrnout'swe:t'egraded using the histologioal. sccre
)tt'oposedby Gleason «())f and acoording to the major
and minor patterns,a total seore (Gleason Soore)
out of 10 waS allooated to each tumour ('l;'able:1).
As indicated Py Gleason, the best diffEu::'entiated
tumours w.tth a tubular growth pattern war. c;yraclQd
1. '.t'n$anapl.astic tumours and tho!;1fllwith single
oell inU 1i::;t'ationWere grader.:lO. The predotni.\1an,tor
m~:iQr pnttlat'n Was 'chen ad('led to thE! lcaesaet'o~ minor
')?attarn ant,;.a total value out of t~n WP.ltlobtainlicl.
The lower the score thQ better dlt:eerentiat$d thtl.l
tumour an6 aCloordin<t to Gleason the bGltter thGl
...19 ..
Ultimate progliosis.
RESULTS
In all spaoimens the AgNOR staining t>1aa olearly
vblible as black nucl.eaz' dots of Varying size. In
ganel'al they were pl.'essnt throughout the nuol.eus
often l)Pli terating the nuc.i.ecaus , The 1ar9'e$t
number 0: NORa Wet'e seen in ti"l.e hi9hest grade o,f
pro~tatic maH<jnatloy (Fi<;1. 2) where as the fewest
NORS were sean in };If!.Inig)').1'rl:lstatio tissue (Fig. :3).
The 9':.:eatest number of. AgNORs Elsen in benign
pr06tatio tiss:16 ,,'I!'tIJ ::7:, pel:' 100 nuclei (Z. 73 pel:.'
oeU) with a mean AgNDR count o~ 3 I 06 pel:' oell
(Table 1).
The 9'reatest nUniper of A9'NC?RSseen in prostatic
Canoer waa 600 per 100 nuoJ,ei (6 per cell) with a
mean AgNORcount. of 4,63 per call (Ta.bl$ 2).
Only 2 of the malignant tumours had AgNOR counts
balot1 400 pe:J:' 100 cella. 'l'he!l,le sUbjeots (casas $16.
& 'laO) had AgNOR Ocli:mt.S of 230 and 278
respeotively, but the A<;1NORSwere unduly l&r9'e ... 2
ot' :3 't.imes the size of N'ORSpresGnt in the other
cases of adenooarcinoma (Fiq. 4)•
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tThe 2 series examined, showed statistically
significant differences in AgNOR staining. When
applying the IItil test via the :Fisoher Behrns
formula a value Of 3,95 was obtaihed (P < 0,01).
Thera is thus a si9'nifioant differemoe in the
staining patt.erns between the 2 set!es.
PISCUSS:J:ON
T.wofaotors emerge from this pilot study. 111hefirst
is that there is a significant differenoe between
the AgNOR staining of benign as oompared to
malignant prostatio epithelial oells. The SeOond is
that. this may prove to be a useful aid in
d.istinguishing well differentiated oaroinoll1afrom
atypical hyperplasia. The AgNOR Cdunt may also
prove to be a Useful aid to the grading of cancer
and may have prognostio importanoe.
The 2 oas(;\sin the lnalignant series demonstrating
low AgNOR counts, with unusuallY larc;legranuler.:t
pr.obab),y represent. fused AgNor granules. The
('.. overall. oount is th~re±'~re pX'obably :farhigher than
estimated. by light mi.orosoopic methodS.
...21 ..
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t
Figure 2. Black silver pr.ecipitation granules or AgNOR
noted in a prostatio adanooaroj.noltla (X 1650) •
...22 ...
tFig1.lre 3. AgNORprecil?itation gral'iules in benign
prostatic epithelium ex 1650)
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iii
Figure 4. Large AgNOR preoipitation granules noted
in 2 oases (X 1660) •
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BENIGN PROSTATIC ENILARGEMENT
AGNOR SIZES
--CASE NO. DIAGNOSIS AGNOR NO.
1 2963 BENIGN 281
2 2910 u " 350
3 2938 /I " 341
4 137 " " 318
5 2912 " II 220
6 584 " " 278
7 637 II " 372
8 646 " " 297
9 451 " " 373-r-1Q.. 527 II " 255 I
11 469 II " 302 1
Mean === 306.45
Standard Deviation === 49.5
Table J,. AgNOR counbs in benign prostatic
epithelium
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ADENOCARCINOMA OF "rHE PROSTATE
AGNOR sizes
CASE NO. DIAGNOSIS TOTAL NO.
1 2910 Carclnolna 410.
2 3568 " " 481..~
:3 3435 " II 541
4 3215 u t1 589-5 249 " t1 514
6 322 11 " 4.:..3.
7 is " " 600
8 58S " " 465
9 645 " II 536",.",",-.--~.,~
10 516 " u 278
11 780 It " 230
Mean;::: 463.8
Standard Deviation ::: 118.96
Table 2. AgNOn cou.nts in prostatic carcinoma.
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t~HAPTER IV
STUDY 2 NUCLEOLAR ORGANIZER REGIONS AND
NEURO-ENDOCRl:NE CELLS l:NPROSTATE CAN'CER
METHODS AND MATERIALS
Fifty-two Patients we~e selected sequ~ntiallY from
the Johannesburg Hospital records ~r:omOctober 19'81
to June 1983. The reco~ds indicated that all Qf
these patients wel"esUbjected to prostatic biopeay
beC'ause of symptollls related to the local
complications of the tUlllOur. In all cases the
pre-operative diagnosis was carcinoma stage S, C ot
D. Twenty-one patients were immediately excluded
from 'chetrial for the following reasons:
(i) Eight had died within 1 month Of surgery. These
deaths were attributed to medi<;~al or surgical
complications Unrelated to the malignant diserje. A
significant number had died of cardio-vascu1ar
complications.
(i~; Five were excluded because no
histor~r was available.
folloW-up
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t~ (iii) In 5 casas no tissue was available for
examination.
(iv) In 3 cases the original diagnosis was
incorrect (transitional ::911carcinoma)
The remaining 31 patients were followed-up to
April 1990 or to date of d9atn. In each case the
cause of death had been doculnente~ and, where
available/ post mortem tissu jequent
sUrgical specimens were examined.
had died 4, 6 and 6.5 years af{
diagnosis. Post mortem material showed. .1'
had died of unrelated causes, and there ~~4 •
evidence of residual prostatic carcinoma. These
post mortem examinations were routine and only 1
tissue block of each prostate was submitted for
histological examination. These 3 patients were
thus.included in the surviving group.
The specimens had been fixed in 10% phosphate
buff9red formalin and processed to wax paraffin.
Four 2 micron sections were cut and tuken to
aqueo.., solutions through grad.eq alcohols. One
section was submitted to the AgNOR staining
procedure at room temperature for 50 minutes (53).
Two sections were submitted to imi'!\unopero}Cidase
staining, polyclona'" Neuron speoific
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Enola$$ ("NSE") (DARO) and Iilol"loolO{lal chrotlog:m:lnin
A ( "ChA") (ENZO). aoth ot these pel'odclase stains
represent markat's of nauro-endoorine oells (64,85).
NSE l."ep.resetlt~ a highly SI3l"lSi'l::iva market' of
nauro ...andoorine cells I \'JhUe ChA, .although l(iisS
sensitive, appal'l:r.s more speloifio (So).
AgNOR TeohniquEl
r.t'haAgNon precip.:i. tation 9l."ant..llEltsWere aSIIHlIssad a8
in Stud.y l. This a3seSSlUent was p~rfot'Iiled without
prio~ knowledge of the pat;l.errts history. Af\ AgNOR
count for each case Was noted.
Immuno).Jero:x:idase T(;IIohnique
Sections st~.il'\ed for ChA and HSE WE're e:x:at\\l.n$r;.\ by
an ind.ependent observer with no knowledge ot thlil
olinical. biatory, and. the IlItainin9 wa~ l:'Goorded all
negative, (no neuro ..endocrine oells seen, ot'
positivQ (individual cells or gl."OUpS ot oelle
ehow.:l.nq positive staining) (Fig- 1$). In 3 cIlU'QS
non"'specific llI~dning was 1,\oted,7this WQS aSSIl!tSIillCiQ
by a .&corHl indep$l'\dent pathologist; '-Ind t'ElGlord!1ldas
neqativE;.
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RESUL'.rS
At the time of follow up (1989)1 11 pa'tientl!l (3G%)
wel:(\I alivQ and wall with no Cllinj.oalevidence of
eli.ease proqt'GI$siont all wst's $hown to bca neqatlvQ
for NSS and ChAt Thl3lthreQ patients who diad ot
unr&latt9d diualllQ wers also naqativGI tor NSlll and
ehA immunoper.'o){idaIlllG ataininq. Of the 17 patiantlS
who diad of' prostatl!t oancer, 15 were pos:lt:l.vliltor
~$lll and 14 for ChAl 2 ot thQ 17 werQ negative fot'
both p~ro~ida$Q stainili.
sut'vival graphs werQ plotted, ol!lmpeu:ing patient.
with pC>$it.i.vQ itfilininq tUlilourR to thollQ with
l'1QqativQ results. Tha total population lIJurvival
QVIat' 7 yearfS (11'1<;1.6) was dOQumGlnted. The tlIurvival
ot t.>atbnt.swhose tumour. were pO$itive for Nsm
were oomparld with thosa n$qativGl tor thl Itain
(1)'i9'. 7) • Similarly lurv! val of pertients with
t.umours podtivGl i!or ahA was QotllplI.rtiHiwith those
ne9t.ttivGl foX' ahA staining (11':1.<1_S). It should b.
);'lot.d that thQ very sig);'lj,f.ioant but b •• stt"iltin<;1
survival ClurV$ noted tor ehA maybe :tQlateQ to its
10w4I): Sf' i!.ttivity OCll1lparlid.with Nsm. The sl'tdkj.n9
t\$.ooiation batw(II$n alurv!val and tumourl nGl(Jativp.!
for n~uro"Qndoo:r."!ne markQrs (l?<O,OOl) wall!notQd
(Fig' • $»). ThG il'ltenlili t;{ 0:1: the sta:l.ning for NSIIland
ahA did not apPQar to bQ related to outC"Ol\\Q•
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tA9NOR oQunts per.formed had a mean count of
579. !5\lOO n1.\011111in tM.I patients dyin<;f of prostate
oanoel:' (SO 15"1. J5). Thra meell'1M1NOn Qount in tha
$urvi \l'1n9' pat.tent' wa. 497. a (SD 116"7). U~in9' the
pool6ld data :for.mul~I.(!I("til test:), a t value of 1,(59
waa obtained, indicat:l.n9 1'\0 si<;rnifiotlnt d.:l.ff'et'snea
at l? III 0,05. IJ:IhitaindicatGld that al.thou9h AqNOR mtly
be usraf.ul in clist:l.n<Ju:l.shinqprostatiC! oaroinoma
from l::Hiiniqn proretatio tapithal ium ( .t.ucly 1), it
appaat's to havcllno value as a prognost.ic indioator.
D!SCUSSION
'rhe OOOtl1":t'QnOiia of neuro"enc:lQorine cells in
prostatic oaroinoma if, variable, dependinq on 1;.\1e
method UIII.«1 to del1'lonltrate thelll aGllls. :en the
pr ••ant stUdy, approdml!l:toly tSO% of the tumours
shoWGd n~ur.o~andoQr.ine differ.entiation, none
histoloc:Jically resCllmblC!d a oal.·oincid tumour or
131\\$11 oall. Q!!trcim:)l'na. 'l'M, tlt<;riiIl:'GlGrdV$b havior Qt
thase tUl.I\Qurs ;1.$ notGlQ from the abovlilIt.at:htios
and is, th6lt'eforGl, oj! tharapautic al'l.Q d;l.aqnostiQ
importanoQ. 1:t has b!ll$nSU9~Qltft$d that chentothGlrap¥
similar to that uSGid for $l\l,all. 0$11 carcinol\ln of
the lun<;l (BE» b$ uS6Icl for Sll1lallcell oarcinoma of
th($!p:r:ollltntli.'rha in:el4$nOe of this new proqnQlltic
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tmarker on the interpretation of the results -'Of
treatment ana the selection of t:r.antanElnt lnodalitil3s
nGleds to bGl 1nvEistiqated.
Finally I WQ propose that al thou9h ~he pl:'elll\ltnc~of
n$\1'l:'o"~ndoor:l.ne cells in othQr tumours (87,ae) may
bEl of no prognostio importanoe, it is of pro<;mollltio
d(:mitioanoe in prostatio oaroinoma. An additional
faotor to Gmet'9Q from the study W'a$ tha finding
that AgNOR mtainin9 appear to have no pr.ognostio
I!d.gn:l.f:!.oanoGl.in p);"otlltatio oaroinoma •
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>rigure IS. !mltlunoperoxidase staining' for chr.'ornOg'raI1inA
( :t:mZo) shows the presenoe of nElur.'o-endocrine
cel.l$ soatttarElC\ in an otherwise well to
moderately-well differentiated carcinoma (X 600) •
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SURVIVAL. OF' TOTAl.. p(~PULATION
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COMPARISON OJ:'rUMOU~S POSITIVE FOR NSE WITH
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COMPARISON OF TUMOURS POSITive FOR ehA
WITH THose NeGATIVe FOR GHA
% SURVIVAL
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Figure 8. s>ur.vival of pati$n'ts positive for
Chroml~"'9ranin A with those who \-1&:1:'$ neqative
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Figure 9. Association between survival and tumours
negative .for nsueo ..endoorine mat'k.ers.
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tCHAPr;t'ERV
STUD':l3 NEURO-EHDOCRINE CELLS 7 A ttEW PROGNOSTIC
PARAMETER IN PROSTATE CANCER
INTRODUCTION
Prognostio indioators in current use
cancer include tumour stagG !U'Id
(35,G). Tumour staging appears to
in prosta.tE><
tumour gradEtt
be rSe:ldily
reproduoible and oort'elates well with patient
survival. By contt'ast, grading systems a;re prone to
individual subjectivity (7,8,9) but are most
aocurate at predictil'lgprognosis at the extr~mes of
grade (well differentiated and poorly
differentiated tumours). The vast majority of
tumours fall into the intermediate grades w~.th an
unprediotable prognosis.
The aim of this st'4dy is to oorrelate the pr09nosis
of prostatio oarcinoma with the presence of
neuro-endocrine oells and to compare this variable
with presen'tly uti lized prognostio ind,toesI name:~yt
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stage and hlstological grade. Neuro-endocrine cells
are indist~uishable on routine light mi.croscopy
from non neuro- endocrine cells and can be detected
only with stains or preferablysilver
in~unopero~idaSe.
METHODS AND MATFRIALS
one hundred and ten patients were selected
sequant,ially from hospital recorp,s at this
institution, from October 19a2 through June 1986.
The records indicated that all patients were
subjected to prostatic biopsy, either by
trans"urethral resection or by needle biopsy
(transrectal). !n all cases the diagnosis w('!.sthat
of carcinoma stage s, c or D. Thi:r.ty..one cases from
Study II were included. No single patient had
:r:eceiv~dany form of therapy prior ,tobiopsy.
Twenty cases Wet'ee~cluded from this stUdy for the
following reas,ons:
1. Five patients had died within onEi month of
surgery. 'rhesedeaths were attribu,ted,topulmona.ry
thrOli\bo-embolicdisease 0;1;to medical complication
unrelated to the prostatic canC(:lr.
2. six patients were e~Cluded due to lal':lKof
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follow"'up history.
a , In 4 cases th£'rewas insufficient tissUe-foc'"
histological examination.
4. In 5 cases the original diagnosis was
(transitional carcinoma [4],
incorrect
metastatic
colo...rectal carcinoma [1]),
The remaining 90 patients wel'efolJ.owed..up to July
1990 o~ date of death. :rneach case the caUse of
dea'thhad been documer+ted , Six patients (including
the 3 from Study II) died.more than 4 year' after
the original diagnosis. In all 6 patien.ts1
postmortem examination conUrm(''''that they had died
of causes um:elat.ed to tnei:t' prostate cancens,
These (;i CafaleSwere inclUded in 'ChI:;.surviving group.
Seventy-seven of the 90 cases Atudied Were
subjected to tra'i'ls-urethra,l.resection and r.tleast
2 rep:r.esen'tative blocks wer.e selected for
examination. In 9 casas needle biopsy material only
was available fOr. assessmemt. A further 4 caseu
underwen't initial needle biopsy and 'due to
obstructive -symptoms, this was followt)d by
trans-urethral resection. In these 4 cases ):loth
needle biopsies and trans"'urethral res$ction
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specimens were examined.
Thirty-one fUrther cases of (Al) occult
adenocaxoi.ncraa were selected sequentially from the
hospi ta:t records, :fromDecember 1988 through l:rune
1990. All casas were found inoidentally at
trans-u:cethral resection performed for benign
prostatic enl.argement. In all cases tumour volume.
was less tllan 4%of the total tissue and was graded
"Gleason" score 7 or less. Ten of these 30 cases
wex'a exoluded as fUrthe:t' sections of the tissue
bloolc. failed to demonst:t:'ate any malignant cells.
All patients with manifest local and regional
disease: (B and C) were initially trea'ted by
radio-therapy. All cases with disseminated disease
(D2) were subjected to an endocrine manipulation
(orchidectomy, "LfHRH"agonists I Or stilbestet'ol).
':0 patient in the series died without $01(113 :Eormof
endocrine manipulation.
All specimens were fixed :i.n 10%pho$ph~te buffered
formalin and processed to WaXparaffin. Three 2
micron sections were cut and taken to aqueous
solutions thrOUgh graded alcohols. One section ~las
stained with r...utine haematoxylin and eosin for
ciiagnosti(J purposes and histological <;trading. Two
..41 ...
tsections were submitted to ill1lllunoperoxidase
staining, na:mely, polyclonal Neuron",specific-
Enolase ("NSE": DAKO) and :monoclonal chromogranin A
("ChAn: ENZO) , both markers of neuro-endocrine
cells.
without knowledge Of clinical nistory or the
patient's records the followi:ng information was
recorded:
J.. Haematioxy LLn and eosin stainler,isections, were
graded accorcHng to llG1easonn J;1_!> major grade and
minor grade I and a GJ.e~lsonscor'e was allocated to
each case.
2. Sect.....ms stained for NSE and ChA were regarded
as negative (no neuro-endocrine cells present) or
positive (individual cells or groups of cells
showing positive $ta.ining) (Fig. l.0,11 & 12).
Two of the 4 needle biopsies in which further
material was a'lfailable for examination showed no
evidence of hlauro-endocrine differentiation.
N'euro-endodrine ells I ho,"1everI were demonstrated
on evaluation of the trans-Urethral biopsy
material. TheSe 2 dase therefore, were considered
positive for neuro~endocrine cells. This
observation confirmed the focal. distribution of
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neuzo-endocrIne cells in pros~~te cancer. A. single
"'needle biopsy may therefore be inadequate in
assessing neuro-endocrdne diffe.t'entiation in a
particular tumour. TWo other important observations
were noted, .nameLy , the presence of neuro-endocrine
cells in benign prostatic gland$ (Fig. 13) as well
as positive staining of nerve twigs by NSE (Fig. 14
& 15). These positive areas were noted but
disregarded in tumour assessment,
At the time of .follow-up (July 1990), 38 patients
from the clirlically Jnanifest group were ali.ve at
least 4 years after the original diagnosis. Another,
6 patients had died of unrelated causes and ~,.ere
included in the total sut'vJ.vingpopUlation of 44.
Forty-six patients had died at' the~:r prostate
cancer. Of the 44 survivors, 5 patients
demonstrated neut'o-endocrine oells in
tumours. Of the 46 that had died as a result Of
their tumours t 42 demonstrateo. naura-endocrine qell
differel"rtiatian (Fig. 16). Of the 4 negative oases,
two oases were representad by a single needle
biopsy. The patients ~Tere classified aocording to
stage (Fig. 11), Gleason major grade (Fig. 16),
Gleason minor grade (Fig. 19) and Gleason score
(Fig. 20). Clinical stage and the presence of
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tprognoetic
histological
significance
indicators (P<
the most
0,0001)
significant
while the
neuro'" endocrine cells were
grading (Gleason) was of
(P= 0,1241). Neuro-endoc:r:ine
less
cells
were ass~ssed for each stage and proved to be a
reliable prognostic indicator in all stages (Fig.
21) •
Neuro-endocrine differentiat'on was demonstrated in
2 cases (10%) of the
examineo, Follow-up of
limited to a maximum
20 occult (Ai) carcinomas
these Cases is, however,
of 2 years With no tumour
progression in any single case.
DISCllSSION
This study conUrms the findings of study II as
weJ.l as ther authors (58,59,67) that appro:dnlately
50% Of clinica.ll.~lmanifest p",.:)statecancer show
neuro-endocrine d.ifferentiation. NO case resembled
a oarcinoid tumour or small cell (oat cell)
carcinoma on histological examination. In earlY
prostate ca'noflr, (pre-ciinical A1 tum6urs) the
incidence of neuro ...endocz Lne .cell differentiation
is approximat.ely 10%. This sugges1::S that the
neuro-endoorine cells may be important in tumour
progression. In add.ition, the prognostic importance
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of neuro-endocrine oells in stage-matched disease
is demonstrated. This prognoEltic factor was
~ignHidantl:y'/ superior to GleaSon's grading system.
In vi<:"·,qof these findings it is s',llggestedthat tbe
presence of neuro-endocrine cell:~ be considered as
an inc1erJendent prognostic variabg. The precise
role of these particular tumour cells is unknown,
but it is specul.atred that they lik~' neuro-endocdne
celli:i in other t.issues I secrete peptide hornones
Whic:)hthen influence the growth of tumour cel.ls and
all,uw th~se to escape anlArogen blockade.
Alterrtati vely
i).1dicate the
neuro-endoord.ne dells may simply
presence of andr<igenresistant cell
cLones, As n9uro-end.l)crine cells are influe"1ced by
other peptide hormones includil1'i1 somatostatin (89)
this should be considered in future therapeutic
trials.
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Figure ;La. I:mmunopero:l(idase stainin<;J for NSE (OAl<O)
shn\4ing positive staining cells in an
otherwise unremarkable carcdrroma (X 820) •
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Figure 11. IXtUnunoperoxidase staining' ;for ChA (ENZO).
positive staining cells hage identical cell
moz-phoLoqy as tlompareCl.to unstained (')ells.
No sl\lI9.11call or oat cell morphology is
noted (X 1650).
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FigQ' 12. ElEu:::tronMicrograph demonstrating dense
cor( ·:~·a.t\ulesin the cytoplasm of prostatic
neuro"'~lldocrine cells (X (820) •
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tFigure 13. Benign neuro-endocrine cells stained with
ChromOg'ranin A noted in entrapped glands
(arrow). The Tumour (right) shows no
staining with Chromogrcmin A (X600).
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Figure 14. Nerve twigs staining with NSE, surrounded
by unstained tumour cells (X 1650).
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Figure 15. l.feuro-endocrine negative cells :i.nfiltrating
positive staining nerves (NSEi x 16f,I).
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Figure 16. survival of patients with .neu.l':'o-endocrine
negative tumours as oompared to patients
with positive tumours.
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Figure 17. patient survival according to clinical
stage.
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Figura 18. 1'21' ientsurvival acoording to Gleason
ntajor grade.
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Figure 19. Pa.tient survival. aooordin<;r to Gleason
minQt' grade.
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tNEURO ..ENDOORINE OELLS If\! STAGED MATCHED CANCER
90 CASES OF PROS1'ArE OANCER WIIH ~ Yr FOLLOW UP
No. SrAGE CANCER DEATHS ALlV(:JNON CANCER DEATHS
22 B 4 (3)* 18 (3)*
20 0 5 (5)* 15(2)*
48 D 37 (34)* 11 (0)*-----------------------------~~------~----0* Posltfve fe., ~leuro·Endocrlne Cells
Figure 21. survival of patients with prostate
canoer aocording to stage and neuro-
endocrine status of tumours.
ADDENDUM
Abrahamsson e.t ar (Abrahamsson PA, Wadstrom LB, Alumets if,
Falk:mer S, and G):'imelius L, pe:ptide-hormone-and-serotonin~
ilfimunoreaotive tultlour cellS in carcinoma of the prostate,
pathology Research and Practice 182: 298-301, 1987) nave
suggested. that if the tissues are preserved in Bouin's fixative,
lleuroendocr.i.ne differentiation is universal in prostate cancer.
This stUdy utilises Silver stains, which it clail.ns to be positive
in all cases stuelied. These cases, i.n addition, where stained
with a battery of polyclonal antisera arid confirmed positive
immuno"'preoi:pitation in 0"'90% of tumou:J:l;J.SeVeral antibodies
used, are not specific to neuroendocrine cells ie. l{CGfound in
plaoental tissue and some germ 01311 tumourS!and leu-enkephaJ.1n
and beta- endorphin found in pe:r.ipheral nerve tissues. SiJ.vOlr
teohniques used in this study are not truly comparable to
i.mmunohistoohemica,ltechnic,{ues, and silVer sdts stain a variety
of mater:i.als including reticulin fibres, nerves, and inflammatory
(.~ells. Other investigators (67) I staining in excess of 300 cases
of prostate cancer I documented neuroendocxane ceUs in only 1.0%
of tumours, using the Grimelius stain on tissues fixed in
formalin or BOl,tinI IS solution.
PolYdlonal neUron speoifio enolase is a, sensitive stain
alth0ugh not always highly specifid. ::enthis thesis we utilise
both monoclonal and polyolonal sera, and analyze the~e
separately. In addi tiori, no :mention is made in the artidle by
Abrahalllssonof a major pitfall of interpretation, documented in
Adelenoum1
this thesis I Le, benLqn neur'oendocr-Lne oells and small neJ;'V'e
twigs entrapped between ncn-rieuroendoer Lne oaroinoma oells,
simulating true neuroendocrine diffex:entiation of the tumour.
This i$ a frequently observed occurrenoe and requires oa:t'etul
histological assessment in distinguishing" benign g-lancts from
carcinoma cells. This would be almost impossiole to achieve using
fluorescent techniques utilised :tn AbrahamssonI s study.
PeroXidase methods used in this thesis enable a far better
assessment of cytolog-ical and arclHteo'f;:.ural detail, neoeasary to
disl..:'ng-uisll benign f.rommalignant glands.
Bouin's fixative oot,taining piCric acid (a), is though'!::.by some
authors to preserve dense core granules,(impo:ttant in the
G:dmelius stain) and their peptide hormones better than 10%
buffered formalin (b). Neuron sPecific enolase used as a
neuroendocrine mar]\:er in this thesis represents a beta- enolaSe
isomer specific to nerve tissues and neuroendoorine cells, but
unrelated to the dense Oore granule. NeUl'onspeoifio enolase is
a highly sensitive marker of neuroendocrine cells present in tl\tt:!
majot.ity of hltluroendocrine tumours (b). Beta-enolase appears to
oeadenatured by .10%buffered formalin onlY after 4 days (lS2) Of
fixation. A recetlt artiole (0) reviewed 20 oases of breast
carc.inome containing cells showing silver precipitation u.sin9 the
G:dmeliu.s teohniqUi:l. Bouin's fixative or formalin was utilised.
All 20 cases were positive for neuron .specific enolase and in
more than half the oases a g:teater pe:tcentage of cells stained
positively for neuron speoific:: enolase than with 't.he Grimelius
technique. Th:i.s appJ.ied to both :formalin fixed tissues and
Addendum2
Bouin's fixation, In this the81(3 only 50%of cases studied were
positive for neuron specific enolase. In radic(il prostatectomy
specimens, neuro....endocrine stains are performed on frozen
seotions, and netl:t'oendocrine features are observed in only 30%....
50% of cases (unpublished data).
If the article by Abrahamsson is ac ;:u:cate and all prostate
cancers shownetrroendocrLnedifferentiation with silver staining I
this may indicate a criti.cal degree of neuro...endocrine
diiferentiation that is not detected in routinely fixed material.
Tumours negati ve in this study may have shown very focal
positivity if processed according-to to.e article by Abrahamsson.
This may represent a deg:t'ee of neuroendocr i.ne oifferentiation
c:t'itical in prognostic evaluation. other studies utilising
methods of fixation similar to that used in this ~hesis have an
yielded an incidence of neuroendocrine differentiation of only
40~50% (57,58,59,60,67,68).
IJ;'hearticle by Abraha)usScnmaycertainly add a new dimt':!nsionto
what is cUrrently known about neuroendocrine cells in prost;ate
cancer. His techniques differ significantly to those used in this
thesis I and the incidence of neuroendocrine detection is in
conta-asb to that or other investigators. This article requires
:further evaluation with parallel imm1lnoperoxida$estudies.
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CHAP'rER VI
STUDY IV: THE BIOCHEMICAL ASSESSMENT OF THE
PROSTATIC NEURO-ENDOCRINE CELL
INTRODUCTION
prostate specific antigen (PSA), a ~Ierineprotease,
is a highly specific marker of beni~'nand malignant
prostatic epitheliu~. virtually all prostate
cancers I (69,77,78) will demonstrate this antigen,
albeit focally, on direct immuno~eroxidase
staining. Serum levels of PSA ar~ to an e~tent
proportional to advancing clinical stage (74).
Considerable overlap, however, exists between
stages, and in the individual case PSA levels are
of qUestionable accuracy in predicting stage of
disease. It is well described that patients with
advanced cancero may only have minimally raised PSA
values (74,79). The explanation of this phenomenon
is poorly addressed in the literature.
Neuro-endocrine cells are a well recognized
component of prostatic ducts and acini (79), and
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tapproximately 50% of prostate cancerS will contain
neuro-endocrine cells. Neuro-endocrine cells in
prostate cancer have been Shown to be of
independent prognostic importance (90,91). The aim
of this study is to correlate on direct
illUllunohistochemical:3taining, the PSA content of
prostatic carcinoma cells with neuro-endocrine
differentiation. Prostate specific acid phosphatase
(PSAP) is also to be assessed in these
neuro-endocrine cells. To the best of .our knowledge
the only previous study that addressed this issue
was a single Case report (60) that described PSAP
and PSA in a single prostatic carcinoid tumour.
Careful revie"'lof this article i nowever I confirmed
that only acid phosphatase had been conclusively
demonstrated in the neuro-endocrine cells. PSA was
demonstrated in the tumour cells but no attempt had
been made to prove these ·very same tumour cells to
be of neuro-endocrine type. The report simply
indicated that PSA containing cells were
morphologically identical on light microscopy to
the neuro+endcor i.necell. In our experience (Study
2 and 3) the neuro-endocrine cell in prostatic
adenocarcinoma is morphologically identical to the
non neuro-endocrine tumour c·1,1. We therefore
question the observation that neuro-endocrine in
this case report produced PSA.
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17-B-Oestradiol is an "estrogen molecule produced
trom circulating testosterone by prostatic
epithelial cells. AS previously mentioned (CHAPTER
I) this molecule is necessary fo,::the normal
development of the prostate and may reflect
anotogen receptor status of prosta.te cancer cells.
Androgen receptors are extremely lab.:He structures
and studies (4.0,41) have shown these to be of
little prognostic importance in prnstate cancer. In
a stlJdy rela.ted to the biOChemical nature of the
neuro-endocrine cell in prostate cancer we Wish to
assess the cell content of this molecule. This
study is facilitated by the development of' a new
anti-17-B- Oestradiol pol.yclonal antibody (83).
METHODS AND ~.TERIALS
Ten cases of neuro-endocrine positive prostate
cancer were selected randomly from the hospital;
records at this Institution. Itt all 10 cases
neuro-endocrine cells reprer',antedbetween 10% and
30% nf the total tumour cell population. FOUr
serial three mic't.'onsections were prepared from
each case. The first section waS stained with
haematoxylin and eosin to confirm the diagnosis of
prostatic adenocarcinoma; the second section was
stained with a monoclonal anti-PSA antibody
(AMERSHAM) and developed with Diaminobenzadine
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("DAB") substrate; the third seetion was stained
with monoclonal anti-PSAP (AMERSHAM) and likewise.
was developed. with the DAB sUbst.rate. The fourth
section \-raastained with anti"17-B-Oestradiol. This
too was developed \oJith DAB and counterstained with
haematoxylin.
pos:!.tive areas wel'e col"Pared In slides 2 and.:3 and'
photographed. Seetion 3 (~nti-pSAP) was resubmitted
to :i.mmunoperoxidasestaining with a speoific marker
of nauro"endocrine cells, mcneol.ona),
anti"Chrom~g-ranin A (ENZO). The stain, however, was
mOdified by thG addition of cobalt. chloride to the
DAB solution (92). This technique confers a
blue-black cOlour to the DAB J?reC::ipitate.This
colour i.s readily discernible from the golelen..
brown colour of unaltereel DAB.
RESULTS
In all 10 cases of prostate carcincma,
neuro-endocni.ne cells positive fOr Chrontogranin A.
fa.lledto stain with PSA :l.mmunoperox:l.da.se(Fig. 22
& 23) . :rmmunoperoxidase stains for PSAp .~.Jnfirmed
the presence of this antigen within the
ne\.lro"endoot'inecell, population (Fig. 24 & 25) in
all cases , A sJ.gnificant nUmber of cellsl negat.we
for nellll:'O-endocrinemarkal: Chrol1\,og'raninA, stained
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positively for PSA and l?SAP (Fig. 26, ~l & 28).
stains ,for 1.7",s-ol!:lstra.diolcou d not be assessed
due to eXC!Msive background precipitation. 'l'hese
stains were repeated several times utilizinq a
variety ot'. blocking ac;ente, varying antibody
titres, and enzyme digestive techniqueG. Despite
t.hese manipu~.ations these stains could not be
interpreted.
DISCUSSION
'l'hisstudy has demonstrated that in 10 cases of
prostate Oancer, neuro-endocrine cells in all cases
failed to secrete PSA in levelS; detectable on
tiSSUe imrnunoperox!dasa staining. 'l'hese oells,
however, p:rodtlceddetectable quantities of l?SAP.
This finding may explain, in pal;'t,the variation of
serum PSA in all stages of prost4te cancer.
Neuro ..endoc:rine cells raqui:r:efurther eval.uation in
prostate cancer subjected to hoX'monal.lnanipu:l.ation.
In this setting 1?SA levelS decline si9nificantl~t.
This finding I hO('levert may not indicate changes in
the l1fauro...endocrine cell population.
Immunohistochemi~al studies of tumours altered by
fully evaluate thehot'mone 't.hetapyat'eneeded to
effeots of thi$ form of theX'apy on the
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neuro-sndoc:dhE\ cell.population in prostate cancer.
It is of some interest that PSAP has been detected
in non"prostatic tleuro""Elndocrine tumours,
particularly of the gastro"'intestinal. trac....(93).
As the neuro"'endocrine cell of the prostate is
thougb:t.to be Of endodermal origin thE:lt'emay b~ a
closer Unk than was previously realized between
the prostatic neuro ....endoorine cell and t.he
gastro"intestinal APtTO cel,):. As the fUnction of
neither 0$11 is in fact known, this b:l.oche).l:ti.cal
link may be the first step in establishing the
fUnction of these cells.
11,.,a-Oestradiol staining was unfortunately not
suocessfUl. 'I'hisWas primarily due to non"'speoific
sta;l.nin9'by the polyclonal anti....bocly. We hope to
overoome this problem in futUre stUdieS with the
Use of a recently deval.oped probe to
5"alpha"reductase I ano'cher i.ndireot meth,od of
assessing the androgen :I';'eoe);\tor•
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Figure 22. A neuro-endoorine positive tumour stailled
with monoolonal pro~tate speoifio antigen
(X 660).
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tFigura 23. A serial section of figure 22 stain~d with
monoclonal Chromcgranin A. The cellS
positi"~ for this mark~r fail to stain
with prot:ltatesp~cific antigen (X 660).
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Figure 24. A neuro-endocrine positive cancer stained
with monoclonal prostatic aoid phosphatase.
DAB substrate was utilized (X 1650) •
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Figure 25. Sect.ion (Figure 24) restained with monoclonal
chrc::>mograninA. DAB / cobalt chloride
sub~:trate was utilized. The neuro+endccrdna
cel]. is identified by plue-black staining.
( arl~OW ) (X 1650) •
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tFigure 26. prostatic adenooaroinoma with neuro-
endoorine cells rtained with monoclonal
prostate specifio antigen. Groups
(arrows) of tumour oells fail to stain
with this marker (X 660).
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\'
Figure 27. Seril:\lsection of tumour shown in Figure 26.
section was stained with monoclonal
Chromogranin A. The groups of tumour cells
noced in Figure 26 stain \'liththis marker
(X 380).
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Figure 28. Serial sacHo ....of tumout' shown in Fjgure :a6.
section was st'ained with monoolonal prostatio;,
acid phosphatase. The groups of tumour cells
noted in Figure 27 stain with this marker
(X 660).
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CHAPTER VII
STUDY 5 THE NORMAL NEtJRO-ENDOCRINE
CELL POPUlATION
INTRODUCTION
.As disc~lssed in CHAPTER 1, there has been no
adequate study addressing the subject of the normal
.occurrence and distribution of the neuro-endocrine
Cell throqgh all stages of prostate development.
Such a study requires the assessment of well
preserved prostatic tissUe, fixed in 10% formalin
for a maximum of 24 hours to prevent excessive
cross linkage and denaturing of antigeni.c sites. J;n
addition, the ntaterial ntuStbe of such a nature
that all zones of the gland are available for
histological and ilnltluno...histological assessment and
contpa:dson. The antibocty, unlike those used in
previous studies (57), should be monoclonal, in
~rder to avoid background precipi tatiorl. large
numbers of.prostate glands need to be examined, to
allow comparison of the of neuro-endocrine cells in
dH ,erent glarlds at dif'ferent stages of
dev.;:lop:ment. l"inally, an accut'ate and objective
counting method Ls necessary to Compare the numbers
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of neuro-endocrine cells in different (~Ol1esand in
diffe~ent prostate glands.
A variety of peptides, includinq calcitonin (68)
and somatostatin (94), have been demonstrated in
the neuro-endocrine cells of the prostate gland.
These studies do not document the distribution of
calcitonin, or somatostatin ~Jroducing cells. The
present study assesses t.henormal occurrence an11
distribution of the neuro-endocrine cell throug',i
a.ll stages of Prostate development, and attempts to
overcome the above ·problems.
MATERIALS AND METHODS
sixty-three intact prostate glands were removed at
autopsy from patients who died of:un~atural deaths,
unrelated to any prostatic disease. These patients
rang-ed in age from 1 month to 70 years. The
atltopsies we:!;'€!performed within 12 hou:!;'sof death
and the prostate glands W.2re fixed in 10% buffered
formalin for 18 to 24 hours. The glands were
sectioned sagittally (Fig. 29) to aUow all zones
to be examined simultaneouslY (fig 30). This
sagittal section was cut in E311Cha manner that the
urethra and ejaculatory duct were present in a
single histological preparation .
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These large tissue seotions (approx. 4.5 X 5.$ om)
wera proc19f3sed through to wax paraUin over a. 24
hour period, and then sectioned on a rotary
microtome at 3 microns. TO facilitate this
procedure, it was necessary to desig'n a special
tissue b1(0)<: (:registered patent number 913715)
\'lhichallowed 't,issuesections of this magnitude to
be prepa:t.'ed(Fig. 31, 32, 33, & Ann'3X1). TWo
serial sections Were cut, one stained with
haemato:x:ylin and eosin, the other with monoclonal
r~ro~ogranin A (ENZO) (Fig. 34).
The ·tissu~ sections were tn.E':lt1examined under a
disseoting microscope and t:.n.eperipn.eral zone,
oentral zone, and tn.e pet-i...urethral glands were
delirl,eated.
'l'he $7 oases were divided into the following
groups: [ *() ""number of cases examined
i) Infcl)nts113013than 3 months of age 'It (2)
ii) pre-pUbertal males {3 months to 13 years) *(5)
Hi) pubertal malel3 {1.4to 18 years) *(5)
iv) Young adults {la to 35 years} *(27)
... 73 ...
v) Middle-aged roales (36 to 50 yea~st *(10)
vi) Elde~ly male;s {50 to eo yea~s} *(9)
Flv.:: Cases were e~cluded. because of
a) Acute Suppurative P~ostatitis 3 casas (!n
which most of the gland had psen destroyed. by an
acute inflammatory proeeas)
b) Poor Tissue l?reparation ....3 Cases
'renhi9h power (Hlp) fields were than :t'andomly
seleQ'eed in each zone and the nun\Per of
neu):'o"'endOCll:'ineeells Per ten Hll? fields tJ/aS
r~oorded. The radius Qf eaoh field measured 0,25
mm1 the ·f;lUl!!f.aoe area O,l9G lU:rn2* anQ, a totU of
ten fields Were assessed (1,96 mm2*). If no
neuro ....~mdoorine oells were noted in 10 H/l? fields
the entire zone in that tissue seotion was exar.ined
under hi9h power magnification and the numbet' of
posj,tivsly staining oells reoorded. The number of
high power fields eXamined pal:'20ne in eaoh seotion
ranged from 36 to 145/ witb a mean of f)a •
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'l'hi:rteencases f:rom the se:ti(:!sof 58 prostat(;i
qlanos were selecteo acoo:ro.i11gto their age
dist:ribution, as indioated belOW.
( *() - number of oases J
i) Infants less than 3 months of age *(1)
ii) Pre"'pubertal ma.les {3 months to 13 years} *(3)
iii) Pube);'talmales {13 years to 18 years} *p.)
iv) Young adul.ts {18 years to 34 years} *(4)
v) Mi,ddle...aged males {36 yea:rs to so years} '* (3)
vi) Elderly males (50 years to SQ years) *(1)
Two f.urther serial sections we:r;e stdned with
polyolonal anti-calo! tonin (PAl(O) and polyolonal.
anti ...somatostatin (PARO) antibody. TheSill seotions
were examined in the sama manner as those stained
:for OhromC!~rE\nin A. Whe:re no staining Was noted in
10 fi~ldS, the 9nt1r$ zone W""s exe.n\i~ed,following
t:ha same protoool as ou·1:.linedfor Cnroml...,;:raninA
st:ainj,ng.
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peri-urethral glands, ~nc).uding the transition
zone, we:t;e,for the purposes of this study, tern\ed
"trEll"; the ductal structures linking the peripheral,
acini to the verumontanum were te:rmed ItNE2u; ana
the acini in the peripheral zone were termed "NllJ3".
With r.egard to calcitonin staining the same zoneS
were termed "Cl", "C2t1 and "C3i1 respaetively.
RESULTS
Thill number o't: positively staining cells is
rapr~lse". ,'.ed it'o Table 3. Values in Nllll and NE2 are
similar and. do not signifioantly differ (p. 0,76).
rrh~ va' UFI$ in N:El3 are sign,'lUcantly lower than
those in e1thar Hl!ll or: Nl!l2 (plio: 0 I 01 I p.... 0,04
rIl1:lgectiveJ.y).As indioated in 'othetable; whel:'eno
oells ~lere obSe):;ved.in ten :fiel.dsthe entire zone
in the 1'l~otion'1as eKamined and the nUl'llberof cells
in ths total, zone was no·ced. Where nO' positively
stained ceUs We;re observed in an entire zone this,
too, was noted.
NeUro··endoorine oellB were seen in the pe;ripheral
zones (NE3) in pre ..pubertal mde"" only auX'ing th~
first few months of life. aetweon 4 anli 13 years no
neuro-endocl:'ine oells were seen in this peripheral
.. 76 ...
t:Ilone(NE3). These cells, however, re-appeared at
appro~imate~y 14 years of age. Following pUberty,
every qase demonstrated a number of neuro-endocrine
cells in the peripheral ZOne. Conversely,
neuro ...endocrine cells were Scen in relatively
constant numbers in the peri-urethral glands (NE1)
and in the prostatic ducts (Nlll::!.) in all age groups,
including pre""pubertal males. It should also be
noted in this group of pre",pUbertal males, that
although neuro ...endoarine cells were not obServed in
the periphel:'alzones of the prostatG gland, large
numberS of neuro ..~mdocrinG cells Were reoorded in
NlU and N1ll2, verifying the adeQuacy of the seain.
Neuro ...endoorine oells in zones NEl and Nlll::!.as W(lll
as the prostatic Ur(!)thl'a(not assessed for this
stuQy) wetc;;Shown to e~h:lbit :f!our mot'phC'l~<Jical
types. one oell type appe,ared ~s a }:;)l.lsally
orientate'd.,i:i'Ilongatedoell with dendritic p:tooesses
(F,i.g. 35)" 'l'he second cell type \'lassuperfic:i.al, I
larger arlc:lrounded t>1ithout visib1.t'lprooesses (Fig.
36). The thitd type of oell, a smalla~ Quboiqal
oell, w~s closel.y appl.1.adto the b~~al l".,ina (rig.
37). A.ll tbe naul:'o"'endoc:d~$ ..~~llls in the
pat'ipharal zone (NE:3) resel':bl(lJ.thE! third basal
type of NEl and NE2 (Fig. :38 $I 39). A fourth call
typa was iclenti:eied in only 2 cases. Il!his oe3.l
appeared 1:1$ an eJ.onga'ted Spi'lldleshaped stromal
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013.11, with slender cytoplasmic prooesses (Fig. 40).
Ca.loitonin
stains for caloitonin demOl'lst:ra.t:ad larger numbers
of calls in areaS C1 and C2 as oOnlparad to area C3.
WhencOlllparing C1 with 02, by means of the Wilooxon
test., the "p" value of C;, 11 WaS not sigl'\ifioant.
Whencomparing C1 bo!d 02 with <:::3 .respectively,
signifioant lip" values Wel.·a obtained (0 I 001 &
0,002).
SOlilatostatin
Stains fol:' somatostatih revealed no staining in any
zone of the pt'ostate glands.
Incidental Sohistosolniasia was dooumented in 1.5, YH:
of oases (F;l.9. 41).
DISCUSSION
Although OiSant: 'Agness (57) noted large nUlu})ars Of
neuro ....enaoorine ceUa in the peri"'uretltt'al area Of
prostate glands removed at radiCl!\l cyst(\lctomy, this
illl tbe first: study to qQll\onstr:a.te ~h$ zonal
... 7a "
distribution of the neuro-endoorine cell in the
nor'mal prostate glandi~ In ad.dition I prostate gla.nds
from pre-pubertal and post"'p,lbertal'males have not
been compared in other studies.
Neuro-endocrine cells in the peri",urethral glands
(NEl), and prostatio ducts (NE2) re'main constant
throughout life. r.t'he fluctuating' levels of
androgens at birth, puberty and old age do not
appear to influence the the number of cells in.
these areas of the g'land. Naut'o-endocrine cells in
the periph.eral zone, h'oweve:r,are postulated to be
present only when androgen leVels are raised,
namelY, the neonatal period under the influenoe Of
maternal progesterone, and post"'pubertal. perioel
under the influence of testicular androgens. The
intervening' years of childhood are charactelized by
loW clrculating androgen levels. The presence Of an
and an androgen
cell raises the
of their being two types of
nl:.ul:to"endoQrinec lls in the different zones of the
prostate gland.
Four, previously undesoribed, morphologioal
va:dants of the naura-endoorine oell in th. area(=!
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been previouslY described in prostatic tissues,
although it has been noted in the mucosa of the
gastro-intestinal tract (95). As these stromal
neuzo ....endoczLne dells were so infrequently
encountered,it :i.spossible that they may represent
a pathological. process, Such as a stromal
metaplastic response to an as yet unidentified
sti.mulus.
Calcitollin staining confir:ms the £it10ing9 of
Disant!AgneSe (68), but again ShOWS a zonal
distribution with little staining in the peripheral
zone. DiSant'Agnese demonstrated positive
somatostatin staining in less than 50% of his eaSElS
(94). This study has failed to confirm thiS
'Ej,neling.
Other studieS have postulated the presence of more
than one type of neuro"'endoorine oell in the
gast"'o-intestinal tract (95) I this raisillg the
possibility Of 2 cell types of different embryonio
origin; the one as indicated by Pearse at al (96)
to be of endodarlltalo:t'igin,the othel of possible
neural crest dad vation. 'llhepreaent observation In
prostate g];ands faVOrS the I;hGory of divergent
differentiation of a.nepithel;l.alstem del.lto form
the neU:l:o"'end.ocrineo ll, in the peripheral zone.
The neuro....andocrine oells of the other 2 regions
..so ...
may well represen'i:.a mixed population, part o;f
which may be of neural crest origin.
The function of the neuro-endocrine cell remains to
be determined. The presence of neuro-endocrine
cells with dendritic procasSes may indicate
intimate association with nerve ti,ssueswhich could
conceivably provide the stimulus for degranulation,
of these cellS. A large number of growth factors
are secreted from nerve tissue (~'7) and these may
be related not only to the function of the normal
prostate gland but also to the "l:Umourmodulating'
function of the prostatic neut'o-endoc:t'inecell
(91) •
Calcitonin receptors in Leydig cellS of the testis
haVe been documented (98), and may be related j,n
part, to the secretion of this hormone by the
prostate gland.
In conclusion it is of import!3.nCethat prostatiC:
neuro-endoorine oe11s and thei1;'proQUots be further
studied as they may provide the solution to the
problem of hormone relapse pl."ostateoaroinoma.
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61
Figura 29. Sagittal section of an entire prostate
gland embedded in paraffin wax.
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Figure 30. A low power field (X 16,5~ of a prostate
gland from a child aged 3 months. The
prosta:d.o urethra (long arrO~ll)~ prostatic
duct system (short arrow); and pe:""'ipheral
acini (open arrow) can pe identified in this
single section (Haemato:x:ylin & eosin).
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Figure 31. Prototype block; designed to cut large
prostate sections,
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t11' .!.gure 32. )?l'ototYP:!l block together with the t:ltandard
lTliQJ:otom~1head •
.. as -
li'iguX'e33. prototype block clamped fil:"mly into the
standard microtome head.
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Ct\\\· •
l1'ic:tul:'e34. Pal:'a:ff in block toc:tethel:' with 2 large slides
one stained with Iiaematoxylin and eosin, the
other stained with Chromoqranin A •
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F~,gu:t:'e35. J?:r,'ostat:l,o epithel.iuuI stained wi.th Chrom~(;p:,aninA
which d.emons't~rates basally o:dentated, el.ongated.
cells with dendritio g~ooe$ses (arrows) (X 660) •
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Figure :~6. l?r.l.';lstatioepithelium stained. with Chr.olUl?graninA
whioh d.emonstr.ates a rounded oell without
oytoplasmio prooeSses (arrow) (X (60).
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Fi9urs 37. P....·ostatic epithelium E.itained with chromog)~anin A
demonstrating small basal neuro-enQocrina oa11$
(arrow) (X 660}.
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Figure 38. l?eripheral zone of pr,)state stdned wi. 1
monocf.ona), chronwgranin A. Small pasal
cells are identified (arrow) ('X 660).
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l"j.gure 39. Prost .!e from infi:mt agec:llone month demonstrating
well-formed prostatia concretions ex 660) .
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/'
Figure 40. str()mal neuro-endocrdne cells stained with
monoclonl!ll ChrolflOc;Jran:ln A (X 6(0) •
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Figure 41. Bilharzia ova irJ..antified in 15,5% of oases
(X 16!)O, Ha.ema.toxylin and eosin).
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TABLE 3
TAULll
No. ChSll No, IIGIl Im~1 NlI-2 NB-1 C-1 C··2 C-3 ntLlIAltZtA
3 1m 1,9 37 17
z i j,n J/, ~O s 16 17
3 79 ',,/r 57 6) 0* 23 19 0*
I, 10 ~/r % 8~ u* ,),) 23 0*
5 1'1 Syr 75 ~2 0*
6 84 9yr 19 \/I 0*
7 71 13yr a~ 36 o·
8 40 16yr 66 60 6 10 I,g
9 81 lGyr It'l 53 10
10 72 17yr 2':Q 103 15
u 70 18yr 189 1"2 3n 15 18yr 100 29 5
13 /7 19yr 212 203 11
111 sa 20 yr 23 21, 2
15 60 21yr NA 'S 3 ,~ . ~-_;
16 59 Zlyr 186 110 3
17 61 21yr 259 172 2
18 25 22yr 180 153 5 +
19 36 22yr 189 150 6 0* 0* 0*
20 65 22yr NA 36 1 +
21 31' 22yr N.'" 62 6 +n 20 21,yr 13 22 6 O' 0* 0"
23 I, 25),r 2~6 129 11
24 5 25),r 11)6 69 29 35 23 0*
t5 I, B 25yr 59 1,0 1
26 ,68 Hyr NA 25 1 1-
27 28 26 'II' 57 31 228 31, 27yr 31, 35 5
29 52 28y\' GS I,S G
30 51, JOyr 190 2\1, +
31 63 .10yr Nil 18 7 l-
32 1,1 10yr 71 lU 6
13 B l0yr t03 1;. 6
:l~ 11, 31yr 79 :;£1 5 1 j 0*
35 1,2 32)'1:' 39 10 S
J6 6 33Y1: ll(, 79 10
37 1 3Sn GO, 27 j( 11, J 0(2) o·
38 1,9 35)'1: 199 104 "39 39 Byt' 75 157 2
1,0 29 38)'1' Z39 Z2\, )7
t.t 5~ 38Y1: Hn 1,2 'I
1,2 S3 39yr NA 119 2
1,3 ~ I, 39)'t' 5·5 27 5
1,1, 13 It!)yr Id 1 0(14) 2 0'"
1,5 Gr, 30 12 3
1,6 15 t.1 yr 111 gl, 31 -l-
/,1 9 1,8:lt' 100 109 2 86 t16 0* +I,n 38 I,9yr lot 30 I,
1,9 1,(1 S.Oj'r 121, 87 II
"'0 33 !d )'r 91 72 tl,
5t 17 ~Sllyt' 64 106 7
52 2 r)Oyr 77 I,e 20 A OOS) 0*
53 % 61yr 33 16 2
~ I, 7 61 )'~ 196 till Nt\
5S 22 ~7)'r 108 121, 156 St 68)'r 5'- 2/, 351 69 70y].' 12 a 3
liOn:
~. tndlqnto" A PoslLtvo Vhllle
It\dl~,nt~$ A Nllllntlvc V'lln"
Nil ·rndlf~n' no 'I'h 0·110 'fhll to Gould Ntl~ lie IIsDl'oscd
( lIlH~m~d or ulcernted)
() _f It,. The N(llIIh~r or Calln In Tho t~lItl a ZOllO
(1 Th.uB s e c t Lo n )
flo nett!! Not$d til The I;ntLrc Zone
(t 'rtnDIlQ Section)
TABLE .~ CONTINUED
NEURO-ENDOCRINE CELL AND CALCITONIN
DISTRIBUTION IN iHE NORMAL PROSiArE GLAND
NS 1 NE2 NE3 C1 C2 C3
Mean 105.0 77.0 7.4 22.0 20.0 0.6
SId.Deviation 69.$ 55.9 8.0 26.$ 32.6 . 1.5
Maximum 289.0 220.0 37,0 BG.O 118.0 4.0
Minimum 1~!.0 7.0 0.0 0.0 0.0 0.0-~'
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CHAPTER vrrr
CONCLUSION
Prostatic aoenocarcinoma is one ot the major causes
of death by malignant disease and will remain So
well ird:o the next century. Fifty years ago
hormonal manipulation was tound to alter the
clinical course of the diseasl;!, ano while some
ea.rly investigators believed in hormonal curElI
lateI' studies confirmed tumour :tEllapse in almost
all cases. It also became apparent that SOmEI
patients relapsed within months While others had a
d:lsease....f l.'eeperiod la~ting many years. Prognostic
parameters including stage r histological g:t:aoef and
a variety of new indices have failed to eXPlain Why
patients with disease of similar stage and grade
have such different responses to therapy and
ultimately a different long..;term prognosis. Ttds
study has attempted to explore two parameters not
previousl.y investigatedr namely nucleolar organiZer
regions and, the prostatic neuro,..enoocrine cell.
NU,cleola.rorganizer regions (NOlt) a.r.eindicators of
chromatin content of the cell and hClve been used in
the Pt'ognostic assessment of many tumours. This
stUdy confirmed, a oorrelation between high valUe
..95 -
NOR counts and malignant prostatic.~pithelium. NOR
counts may therefore be of use in the histological
asaesanent, Of atypical. prostatic epithelium and the
c:listirlction between carcinoma and regenerative
atypia. NOR counts, did not, however, prove to be a
reliable prognostic Index.•
Although the prostatic neuro-endocrine cell has.
been recognized. tor almost a quarter of a centuJ;"jI
very little is kt.\ownabout this cell popul.ation.
This project has attemr 1 .ed ~? define this
population, in tumours as well as in the normal
prosta.te gland. This oe11 has been shown to proviae
a9curate prOgnos',ticinformation on patients with
clinically ma.nifE;!stcarcinomCi..The study has alse
cotlfirmed that occult carcinomas oontain feWE;'lr
neuro-endocrine oells than do more advanced
tumours. The reason for this is unknown I but
implies an involvement of the neur-o'-endccz-Lnecell
in tumour ~rogrpssion.
The biochemical. nature of the neuro-endooz-Ine cell
was investigated and it was demonstrated that this
population unlike most other prostatic tumour
populations; (prior to hormone therapy) fails to
prodUCe prostate specifio antigen (PSA) put
secretes prostatic acid phosphatase (PSAP). Xt ~.s
of interest that PSA is less frequentlY detected in
- 96 ...
tumour cells foUowing anti-androgen therapy. The
presence of neuro-endocr Lna cells.in such recurrent
tumours: has not been addressed, primarily due to
lack of appropriate 't.iSsues. It is suggested,
however, that through future multi-centre
collaborative stUdies this factor be further
inVestigated.
The final chapter of this thesis suggests the
possibility that there may be mor.ethan one type of
neuro-endocrine cell and furthermore that these
cells may be of different embryonic origins. It is
clear that the treatment of advanced prostatic
carcinoma I Which has oVer the past 50 year.$
remained unaltered~ may not significantly improve,
until the functions of the various neuro-endocrine
ceHs are bet'terunde:r:stood.
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